SHORT REVIEW
Chronic Obstructive Pulmonary Disease
 
More details
Hide details
CORRESPONDING AUTHOR
J. Politis
Northeastern Ohio Universities College of Medicine, 500 Gypsy Lane, PO Box 240, Youngstown, Ohio 44501-0240
 
Pneumon 2000;13(1):36–49
 
KEYWORDS
[Article in Greek]
 
REFERENCES (90)
1.
American Thoracic Society Standards for the diagnosis and care of patients with Chronic Obstructive Pulmonary Disease. Am Rev Respir Crit Care Med 1995, 152: 577-620.
 
2.
Sutherland JE et al. Proportionate mortality trends. JAMA 1990, 264: 3178-3184.
 
3.
Ventura SJ et al. Births and Deaths: United States 1996 Monthly Vital Statistics Report Vol 46, No 1, Suppl 2. National Center for Health Statistics, 1997.
 
4.
Feinleib M et al. Trends in COPD mortality in the United States. Am Rev Respir Dis 1989, 140: 59-518.
 
5.
Petty TL. A New National Strategy for COPD. J.Respir Dis 1997, 18(4): 365-369.
 
6.
American Thoracic Society. Standardization of spirometry: 1994 update. Am J Respir Crit Care Med 1995, 152: 1107-1136.
 
7.
Eaton T et al. Spirometry in Primary Care Practice Chest 1999, 116: 416-423.
 
8.
Hankinson JL. Office Spirometry. Does your quality render it impractical? Chest 1999, 116: 276-277.
 
9.
Strategies in preserving lung health and preventing COPD and associated diseases: The National Lung Health Education Program (NHLEP) Chest 1998, 113 (suppl): 1235-1555.
 
10.
Ferguson GT et al. Office spirometry for lung health in adults: a report of the ACCP/NHLBI consensus conference for the National Lung Health Education Program (draft) March 1999.
 
11.
Gross NJ: Practical lessons from the Lung Health Study. J Respir Dis 1995, 16: 162-169.
 
12.
Semmungal TAR et al. Effect of Exacerbation on Quality of Life in Patients with COPD . Am J Respir Crit Care Med 1998, 157: 1418-1422.
 
13.
Connors AF et al. Outcomes following acute exacerbations of severe chronic obstructive lung disease. Am J Respir Crit Care Med 1996, 154: 959-967.
 
14.
Nichol KL et al. Relation Between Influenza Vaccination and Outpatient Visits, Hospitalization and Mortality in Elderly Persons with Chronic Lung Disease. Ann Intern Med 1999, 130: 397-403.
 
15.
Nichol KL et al. Effectiveness of Live, Attenuated Intranasal Influenza Virus Vaccine in Healthy, Working Adults. A randomized controlled trial. JAMA 1999, 282: 137-144.
 
16.
Monto AS et al. Zanamivir in the Prevention of Influenza Among Healthy Adults. JAMA 1999, 282: 31-35.
 
17.
Fletcher C, Peto R: The natural history of chronic airflow obstruction Br Med J 1977, 1645-1648.
 
18.
Bergen AW, Caporaso N: Cigarette Smoking. J Natl Cancer Inst 1999, 91: 1365-1375.
 
19.
Hughes JR et al. Recent Advances in the Pharmacotherapy of Smoking 1999, 281: 72-76.
 
20.
Tonnesen P et al. Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE trial. Eur. Respir. J 1999, 13: 238-246.
 
21.
Hurt RD et al. A comparison of sustained-release bupropion and placebo for smoking cessation. NEJM 1997, 337: 1195-1202.
 
22.
Jorenby DE et al. A controlled trial of sustained release Bupropion, a nicotine patch, or both for smoking cessation. N. Engl. J. Med 1999, 340: 685-691.
 
23.
Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Ann J Respir Crit Care Med 1997, 155: 1283-1289.
 
24.
Celli B, Snider Gil et al. ATS Statement: Standards for the diagnosis and care of patients with COPD. Am J Respir Crit Care Med. 1995, 152: 577-120.
 
25.
Mahler DA et al. Efficacy of Salmeterol Xinafoate in the treatment of COPD. Chest 1999, 115: 957-965.
 
26.
Petty TL. Apples and Oranges. Chest 1999, 116: 1137- 1138.
 
27.
Martin RJ et al. Effect of Ipratropium Bromide Treatment on Oxygen Saturation and Sleep Quality in COPD. Chest 1999, 115: 1338-1345.
 
28.
Dorinsky PM et al. The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD. Chest 1999, 115: 966- 971.
 
29.
Friedman M et al. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest 1999, 115: 636-641.
 
30.
Guyatt GH et al. Bronchodilators in chronic airflow limitation. Am Rev Respir Dis. 1987, 137: 1069-1074.
 
31.
Tsukino M et al. Effects of theophylline and ipratropium bromide on exercise performance in patients with stable COPD. Thorax 1998, 53: 269-273.
 
32.
Karpel JP et al. A comparison of inhaled ipratropium, oral theophylline plus inhaled beta agonist, and the combination of all three in patients with COPD. Chest 1994, 105: 1089-1094.
 
33.
Brenner P et al. Cardiovascular effects of fenoterol under conditions of hypoxemia. Thorax 1992, 47: 814- 817.
 
34.
Cazzola M et al. Cardiac effects of Formoterol and Salmeterol in Patients Suffering from COPD with Preexisting Cardiac Arrhythmias and Hypoxemia. Chest 1998, 114: 411-415.
 
35.
Tranfa CME et al. Short-term Cardiovascular Effects of Salmeterol. Chest 1998, 113:1272-1276.
 
36.
Jenne JW. The debate on S-enantiomers of b-agonists: Tempest in a teapot or gathering storm? N Allergy Clin Immunol 1998, 102: 893-895.
 
37.
Monso E et al. Bacterial infection in COPD. A study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med. 1995, 152: 1316-1320.
 
38.
Eller J et al. Infective exacerbations: Relation between bacteriologic etiology and lung function. Chest 1998, 113: 1542-1548.
 
39.
Soler N et al. Bronchial microbial patterns in severe exacerbations of COPD requiring Mechanical Ventilation. Am J Respir Crit Care Med 1998, 157: 1498-1505.
 
40.
Miravitlles et al. Relationship between bacterial flora in sputum and Functional Impairment in Patients with Acute Exacerbations of COPD. Chest 1999, 116:40-46.
 
41.
Anthonisen NR et al. Antibiotic therapy in acute exacerbations of COPD. Ann Intern Med 1987, 106: 196- 204.
 
42.
Saint S et al. Antibiotics in COPD exacerbations: A meta analysis. JAMA 1995, 273: 957-960.
 
43.
Balter MS et al. Recommendations on the management of chronic bronchitis. Can Med Assoc J 1994, 151(10 suppl): 5-23.
 
44.
Callahan CM et al. Oral corticosteroid therapy for patients with stable COPD: a meta analysis. Ann Intern Med 1991, 114: 216-223.
 
45.
Chanez P et al. Corticosteroid reversibility in COPD is related to features of asthma. Am J Respir Crit Care Med 1997, 15 5: 1529-34.
 
46.
Pizzichini E et al. Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. Am J Respir Crit Care Med 1998, 158: 1511- 1517.
 
47.
Niewoehner DE et al. Effect of Systemic Glucocorticoids in exacerbations of COPD. N Engl J Med 1999, 340: 1941-1947.
 
48.
Davies L et al. Oral corticosteroids in patients admitted to Hospital with exacerbation of COPD: a prospective randomized controlled trial. Lancet 1999, 354: 456- 460.
 
49.
Pauwels RA et al. Long-Term Treatment with Inhaled Budesonide in persons with mild COPD who continue smoking. NEJM 1999, 340: 1948-1953.
 
50.
Vestbo J et al. Copenhagen City Lung Study.
 
51.
Calvelrey PMA et al. Am J Respir Crit Care Med 1999, 159: A 524.
 
52.
Lung Health Study II. Preliminary results. ACCP Meeting, Chicago, November 1999.
 
53.
Saetta M et al. CD8 T-Lymphocytes in Peripheral Airway of smokers with COPD. Am J Respir Crit Care Med 1998, 157: 822-836.
 
54.
Lams BEA et al. Immunopathology of the small airways submucosa in smokers with and without COPD. Am J Respir Crit Care Med 1998, 158: 1518-1523.
 
55.
Lipkin A et al. Otolaryngologist’s role in transtracheal oxygen therapy. Otolaryngol Head Neck Surg 1996, 115: 447-453.
 
56.
Levi-Valensi P et al. Sleep related oxygen desaturation and daytime pulmonary hemodynamics in COPD patients. Eur Respir J 1992, 5: 301-307.
 
57.
Keenan SP et al. Effect of noninvasive positive pressure ventilation on mortality in patients admitted with acute respiratory failure: a meta-analysis. Crit Care Med 1997, 25: 1685-1692.
 
58.
Bach JR et al. Consensus Conference: Noninvasive positive pressure ventilation. Respir Care 1997, 42: 361- 3.
 
59.
Poponick J M et al. Use of Ventilatory Support System (BiPAP) for Acute Respiratory Failure in the Emergency Department. Chest 1999, 116:166-171.
 
60.
Nava S et al. Noninvasive Mechanical Ventilation in Weaning of patients with Respiratory Failure due to COPD. Ann Intern Med 1998, 128:721-728.
 
61.
Girault C et al. Noninvasive Ventilation as a Systematic Extubation and Weaning Technique in Acute-onChronic Respiratory Failure. Am J. Respir. Crit.Care Med. 1999, 160: 86-92.
 
62.
Clinical Indications for Non Invasive Positive Pressure Ventilation in Chronic Respiratory Failure Due to Restrictive Lung Disease, COPD and Nocturnal Hypoventilation-A Concensus Conference Report. Chest 1999, 116: 521-534.
 
63.
Cray-Donald K et al. Nutritional Status and mortality in COPD. Am J Respir Crit Care Med 1996, 153: 961- 966.
 
64.
Schols AMWS et al. Weight loss is a reversible factor in the prognosis of COPD. Am J Respir Crit Care Med 1998, 157: 1791-1797.
 
65.
Burder L et al. Administration of growth hormone to underweight patients with COPD: a prospective, randomized, controlled study. Am J Respir Crit Care Med 1997, 156: 1800-1806.
 
66.
Ferreira IM et al. The influence of a 6 months of oral anabolic steroids on Body Mass and Respiratory Muscles in undernourished COPD patients. Chest 1998, 114: 19-28.
 
67.
Schols AMWJ et al. Plasma Leptin is Related to Proinflammatory Status and Dietary Intake in patients with COPD. Am J Respir Crit Care Med 1999, 160: 1220- 1226.
 
68.
Takabatake N et al. Circulating Leptin in Patients with COPD. Am J Respir Crit Care Med 1999, 159: 1215- 1219.
 
69.
Skeletal Muscle Dysfuction in COPD. A Statement of the American Thoracic Society and the European Respiratory Society. Am J Respir Crit Care Med. 1999, 159: S1-S40.
 
70.
Pulmonary Rehabilitation-1999. The Official Statement of ATS. Am J Respir Crit Care Med 1999, 159: 1666- 1682.
 
71.
Seersholm N, kok Jensen A. Clinical Features and prognosis of life time non-smokers with severe a1-antitrypsin deficiency. Thorax 1998, J3:265-268.
 
72.
Surviral and FEV1 decline in individuals with severe deficiency of a1 antitrypsin. The Alpha 1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med 1998, 158: 49-59.
 
73.
Dirksen A et al. A randomized clinical trial of a1-antitrypsin augmentation therapy. Am J Respir Crit Care Med 1999, 160: 1468-1472.
 
74.
Brantigan O et al. A surgical approach to pulmonary emphysema. Am Rev Respir Dis 1959, 39: 194-202.
 
75.
Cooper J D et al. Bilateral pneumonectony (volume reduction) for chronic obstructive pulmonary disease. J Thorac Cardiovasc Surg 1995, 109: 106-119.
 
76.
Cooper JD, Lefrak SS. Lung-reduction surgery: 5 years on. Lancet 1999, 353 (suppl): 26-27.
 
77.
Fessler HA, Wise RA. Lung Volume Reduction Surgery. Is Less Really More? Am J Respir Crit Care Med. 1999, 159: 1031-1035.
 
78.
Weg IL et al. Development of Pulmonary Hypertension after LVRS. Am J Respir Crit Care Med 1999, 159: 552-556.
 
79.
Sciurba F et al. Six-minute walk testing. Sem Respir Crit Care Med 1998, 19: 383-392.
 
80.
Ferguson G et al. Improved exercise performance following LVRS. Am J Respir Crit Care Med. 1998, 157: 1195-1203.
 
81.
Utz J et al. LVRS for emphysema. Out on a limbo without a NETT. Mayo Clin Proc. 1998, 73: 552-566.
 
82.
Anderson K et al. Comparison of two quality of life measures in patients undergoing lung volume reduction surgery. Am J Respir Crit Care Med 1998, 157(Suppl): A 749.
 
83.
Moy M et al. Quality of life domains of physical activity remain improved at greater than 9 months following LVRS. Am J Respir Crit Care Med 1998, 157 (Suppl): A 496.
 
84.
Brenner M et al. Rate of FEV1 change following LVRS. Chest 1998, 113: 652-659.
 
85.
Gelb AF et al. Serial Lung Function and elastic recoil 2 years after LVRS. Chest 1998, 113:1497-150.
 
86.
Fessler HE, Permutt HS. Lung Volume Reduction Surgery and Airflow Limitation. Am J Respir Crit Care Med 1998, 157: 715-722.
 
87.
Sciurba EC et al. Improvenent in pulmonary function and elastic recoil after lung-reduction surgery for diffuse emphysena. N. Engl. J Med 1996, 334: 1095-1099.
 
88.
Lando Y et al. Effect of LVRS in diaphragm length in severe COPD. Am J Respir Crit Care Med 1999, 159: 796-805.
 
89.
Ingenito EP et al. Relation between preoperative inspiratory lung resistance and the outcome of LVRS for emphysema . N Engl J Med 1998, 338: 1181-1185.
 
90.
Maurer J et al. International Guidelines for the selection of lung transplant candidates. J Heart Lung Transplant 1998, 17: 703 709.
 
eISSN:1791-4914
ISSN:1105-848X